je.st
news
Valeant misses expectations as loses $89 million in Q4, $116M for full year
2013-02-28 23:56:10| Biotech - Topix.net
Valeant Pharmaceuticals International missed expectations as it net loss grew in the fourth-quarter and full-year amid higher operating expenses and items related to restructuring and acquisitions.
Tags: year
full
million
expectations
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||